Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Iodine-125 induces apoptosis via regulating p53, microvessel density, and vascular endothelial growth factor in colorectal cancer

Authors: Zhenhuan Ma, Yong Yang, Guokai Yang, Jia Wan, Guojian Li, Ping Lu, Lingjuan Du

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Iodine interstitial brachytherapy has been widely reported for treating colorectal cancer (CRC). However, the inhibitory molecular mechanism of iodine-125 (I-125) on CRC has not been reported.

Methods

To illustrate the inhibitory mechanism of iodine-125 (I-125) on CRC, we established the animal models of CRC via the injection of HCT-8 cells into nude mice. Subsequently, the I-125 granules were implanted into the tumor of the animal model at different dosages. Proliferating cell nuclear antigen and terminal transferase dUTP nick end labeling were used to detect the apoptosis of the tumor cells. Immunohistochemistry SP staining was used to measure the expression of p53 protein. The protein levels were examined with western blot and ELISA. Meanwhile, microvessel density (MVD) was counted by endothelial cells immunostained by anti-CD34 antibody.

Results

The results showed that I-125 protests against CRC via increasing the protein level of p53 and decreasing the level of vascular endothelial growth factor (VEGF), leading to the decrease of MVD in CRC (P <0.0001). An effective inhibition dosage of I-125 ranged from 0.4 to 0.8 mCi.

Conclusions

The inhibitory mechanisms of iodine on CRC acted through an increase in the level of p53 and a decrease in the level of VEGF, resulting in a decrease of MVD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
2.
go back to reference Zhang H, Li X, Ding J, Xu H, Dai X, Hou Z, Zhang K, Sun K, Sun W: Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm. 2013, 441: 261-268. 10.1016/j.ijpharm.2012.11.034.CrossRefPubMed Zhang H, Li X, Ding J, Xu H, Dai X, Hou Z, Zhang K, Sun K, Sun W: Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm. 2013, 441: 261-268. 10.1016/j.ijpharm.2012.11.034.CrossRefPubMed
3.
go back to reference Morris EJ, Taylor EF, Thomas JD, Quirke P, Finan PJ, Coleman MP, Rachet B, Forman D: Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut. 2011, 60: 806-813. 10.1136/gut.2010.232181.CrossRefPubMed Morris EJ, Taylor EF, Thomas JD, Quirke P, Finan PJ, Coleman MP, Rachet B, Forman D: Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut. 2011, 60: 806-813. 10.1136/gut.2010.232181.CrossRefPubMed
4.
go back to reference Glabbeke MV, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay J-Y: Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG). Eur J Cancer. 2006, 42: 2277-2285. 10.1016/j.ejca.2006.03.029.CrossRefPubMed Glabbeke MV, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay J-Y: Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG). Eur J Cancer. 2006, 42: 2277-2285. 10.1016/j.ejca.2006.03.029.CrossRefPubMed
5.
go back to reference Ni RH, Wang G, Zhang ZM, Ma JG: Iodine-125 seed implantation in the treatment of sacrococcygeal chordoma: a case report. Cell Biochem Biophys. 2012, 64: 107-113. 10.1007/s12013-012-9378-6.CrossRefPubMed Ni RH, Wang G, Zhang ZM, Ma JG: Iodine-125 seed implantation in the treatment of sacrococcygeal chordoma: a case report. Cell Biochem Biophys. 2012, 64: 107-113. 10.1007/s12013-012-9378-6.CrossRefPubMed
6.
go back to reference Buckstein M, Carpenter TJ, Stone NN, Stock RG: Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up. Urology. 2013, 81: 364-369. 10.1016/j.urology.2012.08.112.CrossRefPubMed Buckstein M, Carpenter TJ, Stone NN, Stock RG: Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up. Urology. 2013, 81: 364-369. 10.1016/j.urology.2012.08.112.CrossRefPubMed
7.
go back to reference Basha G, Penninckx F, Mebis J, Filez L, Geboes K, Yap P: Local and systemic effects of intraoperative whole-colon washout with 5 per cent povidone-iodine. Br J Surg. 1999, 86: 219-226. 10.1046/j.1365-2168.1999.01011.x.CrossRefPubMed Basha G, Penninckx F, Mebis J, Filez L, Geboes K, Yap P: Local and systemic effects of intraoperative whole-colon washout with 5 per cent povidone-iodine. Br J Surg. 1999, 86: 219-226. 10.1046/j.1365-2168.1999.01011.x.CrossRefPubMed
8.
go back to reference Percivale P, Bertoglio S, Meszaros P, Schenone F, Gipponi M, Moresco L, Cosso M, Badellino F: Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer. Semin Surg Oncol. 1998, 15: 231-234. 10.1002/(SICI)1098-2388(199812)15:4<231::AID-SSU9>3.0.CO;2-G.CrossRefPubMed Percivale P, Bertoglio S, Meszaros P, Schenone F, Gipponi M, Moresco L, Cosso M, Badellino F: Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer. Semin Surg Oncol. 1998, 15: 231-234. 10.1002/(SICI)1098-2388(199812)15:4<231::AID-SSU9>3.0.CO;2-G.CrossRefPubMed
9.
go back to reference Liu R, Luo F, Zhang Z, Xu Y: Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer. Clin Genitourin Cancer. 2013, 11: 251-255. 10.1016/j.clgc.2012.12.010.CrossRefPubMed Liu R, Luo F, Zhang Z, Xu Y: Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer. Clin Genitourin Cancer. 2013, 11: 251-255. 10.1016/j.clgc.2012.12.010.CrossRefPubMed
10.
go back to reference da Silva Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB: Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy. Brachytherapy. 2010, 9: 307-312. 10.1016/j.brachy.2009.07.011.CrossRefPubMed da Silva Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB: Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy. Brachytherapy. 2010, 9: 307-312. 10.1016/j.brachy.2009.07.011.CrossRefPubMed
11.
go back to reference Chen JB, Li JL, He LH, Liu WQ, Yao F, Zeng JY, Zhang Y, Xu KQ, Niu LZ, Zuo JS, Xu KC: Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J Gastroenterol. 2012, 18: 7056-7062. 10.3748/wjg.v18.i47.7056.PubMedCentralCrossRefPubMed Chen JB, Li JL, He LH, Liu WQ, Yao F, Zeng JY, Zhang Y, Xu KQ, Niu LZ, Zuo JS, Xu KC: Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J Gastroenterol. 2012, 18: 7056-7062. 10.3748/wjg.v18.i47.7056.PubMedCentralCrossRefPubMed
12.
go back to reference Liu XH, Chen GG, Vlantis AC, Tse GM, van Hasselt CA: Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. Mol Cell Endocrinol. 2010, 320: 128-135. 10.1016/j.mce.2010.02.004.CrossRefPubMed Liu XH, Chen GG, Vlantis AC, Tse GM, van Hasselt CA: Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. Mol Cell Endocrinol. 2010, 320: 128-135. 10.1016/j.mce.2010.02.004.CrossRefPubMed
13.
go back to reference Rosner H, Torremante P, Moller W, Gartner R: Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis. Exp Clin Endocrinol Diabetes. 2010, 118: 410-419. 10.1055/s-0029-1225615.CrossRefPubMed Rosner H, Torremante P, Moller W, Gartner R: Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis. Exp Clin Endocrinol Diabetes. 2010, 118: 410-419. 10.1055/s-0029-1225615.CrossRefPubMed
14.
go back to reference Yokoyama A, Tanaka Y, Yokoyama T, Mizukami T, Matsui T, Maruyama K, Omori T: p53 protein accumulation, iodine-unstained lesions, and alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 genotypes in Japanese alcoholic men with esophageal dysplasia. Cancer Lett. 2011, 308: 112-117. 10.1016/j.canlet.2011.04.020.CrossRefPubMed Yokoyama A, Tanaka Y, Yokoyama T, Mizukami T, Matsui T, Maruyama K, Omori T: p53 protein accumulation, iodine-unstained lesions, and alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 genotypes in Japanese alcoholic men with esophageal dysplasia. Cancer Lett. 2011, 308: 112-117. 10.1016/j.canlet.2011.04.020.CrossRefPubMed
15.
go back to reference Yang L, Zhou J, Ma Q, Wang C, Chen K, Meng W, Yu Y, Zhou Z, Sun X: Knockdown of PPAR delta gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model. PLoS One. 2013, 8: e60715-10.1371/journal.pone.0060715.PubMedCentralCrossRefPubMed Yang L, Zhou J, Ma Q, Wang C, Chen K, Meng W, Yu Y, Zhou Z, Sun X: Knockdown of PPAR delta gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model. PLoS One. 2013, 8: e60715-10.1371/journal.pone.0060715.PubMedCentralCrossRefPubMed
16.
go back to reference Thalheimer A, Illert B, Bueter M, Gattenlohner S, Stehle D, Gasser M, Thiede A, Waaga-Gasser AM, Meyer D: Feasibility and limits of an orthotopic human colon cancer model in nude mice. Comp Med. 2006, 56: 105-109.PubMed Thalheimer A, Illert B, Bueter M, Gattenlohner S, Stehle D, Gasser M, Thiede A, Waaga-Gasser AM, Meyer D: Feasibility and limits of an orthotopic human colon cancer model in nude mice. Comp Med. 2006, 56: 105-109.PubMed
17.
go back to reference Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, Trugnan G: Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis. 1995, 16: 245-252. 10.1093/carcin/16.2.245.CrossRefPubMed Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, Trugnan G: Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis. 1995, 16: 245-252. 10.1093/carcin/16.2.245.CrossRefPubMed
18.
go back to reference Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B: Antitumor activities of recombinant human interferon (IFN)-lambda1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. 2011, 311: 141-151. 10.1016/j.canlet.2011.07.004.CrossRefPubMed Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B: Antitumor activities of recombinant human interferon (IFN)-lambda1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. 2011, 311: 141-151. 10.1016/j.canlet.2011.07.004.CrossRefPubMed
19.
go back to reference Shiao YH, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, Saieva C, Masala G, Fraumeni JF, Rice JM: Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev. 2000, 9: 631-633.PubMed Shiao YH, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, Saieva C, Masala G, Fraumeni JF, Rice JM: Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev. 2000, 9: 631-633.PubMed
20.
21.
go back to reference Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55: 3964-3968.PubMed Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55: 3964-3968.PubMed
22.
go back to reference Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S: Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007, 97: 391-397. 10.1038/sj.bjc.6603875.PubMedCentralCrossRefPubMed Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S: Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007, 97: 391-397. 10.1038/sj.bjc.6603875.PubMedCentralCrossRefPubMed
23.
go back to reference Leon SP, Folkerth RD, Black PML: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996, 77: 362-372. 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z.CrossRefPubMed Leon SP, Folkerth RD, Black PML: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996, 77: 362-372. 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z.CrossRefPubMed
24.
go back to reference Chong BE, Yan F, Lubman DM, Miller FR: Chromatofocusing nonporous reversed‒phase high‒performance liquid chromatography/electrospray ionization time‒of‒flight mass spectrometry of proteins from human breast cancer whole cell lysates: a novel two‒dimensional liquid chromatography/mass spectrometry method. Rapid Commun Mass Spectrom. 2001, 15: 291-296. 10.1002/rcm.227.CrossRefPubMed Chong BE, Yan F, Lubman DM, Miller FR: Chromatofocusing nonporous reversed‒phase high‒performance liquid chromatography/electrospray ionization time‒of‒flight mass spectrometry of proteins from human breast cancer whole cell lysates: a novel two‒dimensional liquid chromatography/mass spectrometry method. Rapid Commun Mass Spectrom. 2001, 15: 291-296. 10.1002/rcm.227.CrossRefPubMed
25.
go back to reference Shimada H, Ochiai T, Nomura F: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer. 2003, 97: 682-689. 10.1002/cncr.11092.CrossRefPubMed Shimada H, Ochiai T, Nomura F: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer. 2003, 97: 682-689. 10.1002/cncr.11092.CrossRefPubMed
26.
go back to reference Yamagata M, Shiratori Y, Dan Y, Shiina S, Takayama T, Makuuchi M, Omata M: Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol. 2000, 11: 761-762. 10.1023/A:1008318526938.CrossRefPubMed Yamagata M, Shiratori Y, Dan Y, Shiina S, Takayama T, Makuuchi M, Omata M: Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol. 2000, 11: 761-762. 10.1023/A:1008318526938.CrossRefPubMed
27.
go back to reference Zhang DQ, Guo Q, Zhu JH, Chen WC: Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol. 2013, 11: 16-23. 10.1186/1477-7819-11-16.PubMedCentralCrossRefPubMed Zhang DQ, Guo Q, Zhu JH, Chen WC: Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol. 2013, 11: 16-23. 10.1186/1477-7819-11-16.PubMedCentralCrossRefPubMed
28.
go back to reference Mullany LK, Liu Z, Wong KK, Deneke V, Ren YA, Herron A, Richards JS: Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol. 2014, 28: 127-137. 10.1210/me.2013-1308.PubMedCentralCrossRefPubMed Mullany LK, Liu Z, Wong KK, Deneke V, Ren YA, Herron A, Richards JS: Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol. 2014, 28: 127-137. 10.1210/me.2013-1308.PubMedCentralCrossRefPubMed
29.
go back to reference Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006, 3: 24-40.CrossRefPubMed Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006, 3: 24-40.CrossRefPubMed
30.
go back to reference Niu L, Zhou L, Xu K, Mu F: Combination of cryosurgery and Iodine-125 seeds brachytherapy for lung cancer. J Thorac Dis. 2012, 4: 504-507.PubMedCentralPubMed Niu L, Zhou L, Xu K, Mu F: Combination of cryosurgery and Iodine-125 seeds brachytherapy for lung cancer. J Thorac Dis. 2012, 4: 504-507.PubMedCentralPubMed
31.
go back to reference Jarusevicius L, Inciura A, Juozaityte E, Vaiciunas K, Vaitkus A, Sniureviciute M: Comparison of implant quality between loose and intra-operatively linked iodine-125 seeds in prostate cancer brachytherapy. J Radiat Res. 2012, 53: 439-446.CrossRefPubMed Jarusevicius L, Inciura A, Juozaityte E, Vaiciunas K, Vaitkus A, Sniureviciute M: Comparison of implant quality between loose and intra-operatively linked iodine-125 seeds in prostate cancer brachytherapy. J Radiat Res. 2012, 53: 439-446.CrossRefPubMed
32.
go back to reference Chen K, Xia Y, Wang H, Xiao F, Xiang G, Shen F: Adjuvant iodine-125 Brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One. 2013, 8: e57397-10.1371/journal.pone.0057397.PubMedCentralCrossRefPubMed Chen K, Xia Y, Wang H, Xiao F, Xiang G, Shen F: Adjuvant iodine-125 Brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One. 2013, 8: e57397-10.1371/journal.pone.0057397.PubMedCentralCrossRefPubMed
33.
go back to reference Fang Z, Yan Z, Luo J, Liu Q, Qu X, Zhang W, Liu L, Wu L, Wang J: Evaluation of endovascular placement of iodine-125 seed straund combined with transcatheter arterial chemoembolization for treating hepatocellular carcinoma with extensive portal vein tumor thrombus. Chin J Hepatol. 2013, 21: 146-149. Fang Z, Yan Z, Luo J, Liu Q, Qu X, Zhang W, Liu L, Wu L, Wang J: Evaluation of endovascular placement of iodine-125 seed straund combined with transcatheter arterial chemoembolization for treating hepatocellular carcinoma with extensive portal vein tumor thrombus. Chin J Hepatol. 2013, 21: 146-149.
34.
go back to reference Huang Q, Chen J, Chen Q, Lai Q, Cai S, Luo K, Lin Z: Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol. 2013, 82: 2061-2066. 10.1016/j.ejrad.2013.05.037.CrossRefPubMed Huang Q, Chen J, Chen Q, Lai Q, Cai S, Luo K, Lin Z: Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol. 2013, 82: 2061-2066. 10.1016/j.ejrad.2013.05.037.CrossRefPubMed
35.
go back to reference Ishida M, Sugawara A, Matsushima M, Ohara R, Katayama M, Nakajima Y: Rectal injury during permanent seed implantation for prostate Brachytherapy. Jpn J Clin Oncol. 2012, 42: 1207-1210. 10.1093/jjco/hys165.CrossRefPubMed Ishida M, Sugawara A, Matsushima M, Ohara R, Katayama M, Nakajima Y: Rectal injury during permanent seed implantation for prostate Brachytherapy. Jpn J Clin Oncol. 2012, 42: 1207-1210. 10.1093/jjco/hys165.CrossRefPubMed
36.
go back to reference Stone NN, Gerber NK, Blacksburg S, Stone J, Stock RG: Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. J Urol. 2012, 187: 117-123. 10.1016/j.juro.2011.09.045.CrossRefPubMed Stone NN, Gerber NK, Blacksburg S, Stone J, Stock RG: Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. J Urol. 2012, 187: 117-123. 10.1016/j.juro.2011.09.045.CrossRefPubMed
37.
go back to reference Takahashi Y, Bucana CD, Cleary KR, Ellis LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer. 1998, 79: 34-38. 10.1002/(SICI)1097-0215(19980220)79:1<34::AID-IJC7>3.0.CO;2-X.CrossRefPubMed Takahashi Y, Bucana CD, Cleary KR, Ellis LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer. 1998, 79: 34-38. 10.1002/(SICI)1097-0215(19980220)79:1<34::AID-IJC7>3.0.CO;2-X.CrossRefPubMed
38.
go back to reference Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997, 132: 541-546. 10.1001/archsurg.1997.01430290087018.CrossRefPubMed Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997, 132: 541-546. 10.1001/archsurg.1997.01430290087018.CrossRefPubMed
39.
go back to reference Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, Saulquin X, Fuks Z, Gaugler M-H, Kolesnick R, Paris F: Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res. 2010, 70: 9905-9915. 10.1158/0008-5472.CAN-10-2043.CrossRefPubMed Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, Saulquin X, Fuks Z, Gaugler M-H, Kolesnick R, Paris F: Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res. 2010, 70: 9905-9915. 10.1158/0008-5472.CAN-10-2043.CrossRefPubMed
40.
go back to reference Bassett JK, Severi G, English DR, Baglietto L, Krishnan K, Hopper JL, Giles GG: Body size, weight change, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 2010, 19: 2978-2986. 10.1158/1055-9965.EPI-10-0543.CrossRefPubMed Bassett JK, Severi G, English DR, Baglietto L, Krishnan K, Hopper JL, Giles GG: Body size, weight change, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 2010, 19: 2978-2986. 10.1158/1055-9965.EPI-10-0543.CrossRefPubMed
41.
go back to reference Laake I, Thune I, Selmer R, Tretli S, Slattery ML, Veierod MB: A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon. Cancer Epidemiol Biomarkers Prev. 2010, 19: 1511-1522. 10.1158/1055-9965.EPI-09-0813.CrossRefPubMed Laake I, Thune I, Selmer R, Tretli S, Slattery ML, Veierod MB: A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon. Cancer Epidemiol Biomarkers Prev. 2010, 19: 1511-1522. 10.1158/1055-9965.EPI-09-0813.CrossRefPubMed
42.
go back to reference Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS: Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008, 26: 4109-4115. 10.1200/JCO.2007.15.6687.PubMedCentralCrossRefPubMed Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS: Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008, 26: 4109-4115. 10.1200/JCO.2007.15.6687.PubMedCentralCrossRefPubMed
43.
go back to reference de Vries E, Soerjomataram I, Lemmens VE, Coebergh JW, Barendregt JJ, Oenema A, Moller H, Brenner H, Renehan AG: Lifestyle changes and reduction of colon cancer incidence in Europe: a scenario study of physical activity promotion and weight reduction. Eur J Cancer. 2010, 46: 2605-2616. 10.1016/j.ejca.2010.07.040.CrossRefPubMed de Vries E, Soerjomataram I, Lemmens VE, Coebergh JW, Barendregt JJ, Oenema A, Moller H, Brenner H, Renehan AG: Lifestyle changes and reduction of colon cancer incidence in Europe: a scenario study of physical activity promotion and weight reduction. Eur J Cancer. 2010, 46: 2605-2616. 10.1016/j.ejca.2010.07.040.CrossRefPubMed
44.
go back to reference Baicus C, Caraiola S, Rimbas M, Patrascu R, Baicus A, Gsspi : Ferritin above 100 mcg/L could rule out colon cancer, but not gastric or rectal cancer in patients with involuntary weight loss. BMC Gastroenterol. 2012, 12: 86-92. 10.1186/1471-230X-12-86.PubMedCentralCrossRefPubMed Baicus C, Caraiola S, Rimbas M, Patrascu R, Baicus A, Gsspi : Ferritin above 100 mcg/L could rule out colon cancer, but not gastric or rectal cancer in patients with involuntary weight loss. BMC Gastroenterol. 2012, 12: 86-92. 10.1186/1471-230X-12-86.PubMedCentralCrossRefPubMed
45.
go back to reference Kobayashi M, Wakabayashi H, Kojima H, Konishi T, Okuda K, Yoneyama H, Kayano D, Tobisaka M, Tsushima H, Onoguchi M: Prototype imaging protocols for monitoring the efficacy of iodine-131 ablation in differentiated thyroid cancer. Hell J Nucl Med. 2013, 16: 175-180.PubMed Kobayashi M, Wakabayashi H, Kojima H, Konishi T, Okuda K, Yoneyama H, Kayano D, Tobisaka M, Tsushima H, Onoguchi M: Prototype imaging protocols for monitoring the efficacy of iodine-131 ablation in differentiated thyroid cancer. Hell J Nucl Med. 2013, 16: 175-180.PubMed
46.
go back to reference Moon JA, Yoo CH, Kim MH, Lee SM, Oh YJ, Ryu YH, Lee YS, Chang HS, Park CS, Lee KE: Knowledge, self-efficacy, and perceived barriers on the low-iodine diet among thyroid cancer patients preparing for radioactive iodine therapy. Clin Nutr Res. 2012, 1: 13-22. 10.7762/cnr.2012.1.1.13.PubMedCentralCrossRefPubMed Moon JA, Yoo CH, Kim MH, Lee SM, Oh YJ, Ryu YH, Lee YS, Chang HS, Park CS, Lee KE: Knowledge, self-efficacy, and perceived barriers on the low-iodine diet among thyroid cancer patients preparing for radioactive iodine therapy. Clin Nutr Res. 2012, 1: 13-22. 10.7762/cnr.2012.1.1.13.PubMedCentralCrossRefPubMed
47.
go back to reference Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL: Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther. 2012, 19: 659-665. 10.1038/cgt.2012.47.CrossRefPubMed Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL: Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther. 2012, 19: 659-665. 10.1038/cgt.2012.47.CrossRefPubMed
48.
go back to reference Almeida JP, Sanabria AE, Lima EN, Kowalski LP: Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011, 33: 686-690. 10.1002/hed.21520.CrossRefPubMed Almeida JP, Sanabria AE, Lima EN, Kowalski LP: Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011, 33: 686-690. 10.1002/hed.21520.CrossRefPubMed
49.
go back to reference Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM: Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009, 50: 1605-1610. 10.2967/jnumed.108.061382.CrossRefPubMed Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM: Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009, 50: 1605-1610. 10.2967/jnumed.108.061382.CrossRefPubMed
Metadata
Title
Iodine-125 induces apoptosis via regulating p53, microvessel density, and vascular endothelial growth factor in colorectal cancer
Authors
Zhenhuan Ma
Yong Yang
Guokai Yang
Jia Wan
Guojian Li
Ping Lu
Lingjuan Du
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-222

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue